REVIVA PHARMACEUTICALS HOLDINGS, INC. Research And Development Expense

Quick Answer

REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Research And Development Expense of $11.71 million for the year ending 2025.

  • REVIVA PHARMACEUTICALS HOLDINGS, INC. showed a decrease of -48.9% in Research And Development Expense from 2024 to 2025.
  • This data is from REVIVA PHARMACEUTICALS HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2019 to 2025), REVIVA PHARMACEUTICALS HOLDINGS, INC.'s Research And Development Expense has grown by 5,881.7%.
  • Historical annual values: Fiscal year 2025: $11.71 million | Fiscal year 2024: $22.91 million | Fiscal year 2023: $31.42 million | Fiscal year 2022: $22.87 million | Fiscal year 2021: $4.85 million | Fiscal year 2021: $4.85 million | Fiscal year 2020: $295.2 thousand | Fiscal year 2019: $195.7 thousand.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: